Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia

Yuan Hung Yeh, Junn Liang Chang, Pei Ching Hsiao, Shih Ming Tsao, Chien Huang Lin, Shang Jyh Kao, Ming Chih Chou, Shun Fa Yang, Ming Hsien Chien

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

Background: The aim of this study was to investigate the differential plasma levels of lipocalin 2 (LCN2) and its complex with MMP-9 (where MMP is matrix metalloproteinase) before and after antibiotic treatment in hospitalized adult patients with community-acquired pneumonia (CAP). Method: Plasma LCN2 and LCN2/MMP-9 complex levels were measured in 61 adult patients with CAP and 60 healthy controls using commercial enzyme-linked immunosorbent assay (ELISA). Results: A decrease in the number of white blood cells (WBCs) and neutrophils and decreases in the levels of C-reactive protein (CRP), LCN2, and LCN2/MMP-9 complex were observed after antibiotic treatment. The plasma level of LCN2, but not that of CRP, was correlated with the severity of CAP based on the Pneumonia Severity Index (PSI; r = 0.333, P = 0.009), confusion, urea, respiratory rate and blood pressure (CURB)-65 (r = 0.288, P = 0.024), and Acute Physiology And Chronic Health Evaluation II (APACHE II) scores (r = 0.328, P = 0.010). LCN2 levels were also significantly correlated with LCN2/MMP-9 levels and the numbers of WBCs or neutrophils. Conclusions: Plasma levels of LCN2 and the LCN2/MMP-9 complex can act as adjuvant diagnostic biomarkers for CAP. Plasma LCN2 might play a further role in the clinical assessment of the severity of CAP, which could potentially guide the development of future treatment strategies.
原文英語
頁(從 - 到)253-260
頁數8
期刊Journal of Clinical Laboratory Analysis
27
發行號4
DOIs
出版狀態已發佈 - 七月 2013

指紋

Lipocalins
Pneumonia
Matrix Metalloproteinases
Plasmas
C-Reactive Protein
Neutrophils
Leukocytes
Lipocalin-2
Blood
Anti-Bacterial Agents
Immunosorbents
APACHE
Blood pressure
Physiology
Biomarkers
Respiratory Rate
Urea
Assays
Therapeutics
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Medical Laboratory Technology
  • Microbiology (medical)
  • Immunology and Allergy
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Biochemistry, medical
  • Clinical Biochemistry

引用此文

Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia. / Yeh, Yuan Hung; Chang, Junn Liang; Hsiao, Pei Ching; Tsao, Shih Ming; Lin, Chien Huang; Kao, Shang Jyh; Chou, Ming Chih; Yang, Shun Fa; Chien, Ming Hsien.

於: Journal of Clinical Laboratory Analysis, 卷 27, 編號 4, 07.2013, p. 253-260.

研究成果: 雜誌貢獻文章

Yeh, Yuan Hung ; Chang, Junn Liang ; Hsiao, Pei Ching ; Tsao, Shih Ming ; Lin, Chien Huang ; Kao, Shang Jyh ; Chou, Ming Chih ; Yang, Shun Fa ; Chien, Ming Hsien. / Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia. 於: Journal of Clinical Laboratory Analysis. 2013 ; 卷 27, 編號 4. 頁 253-260.
@article{ac82500acfec469c8971046dc0ae2585,
title = "Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia",
abstract = "Background: The aim of this study was to investigate the differential plasma levels of lipocalin 2 (LCN2) and its complex with MMP-9 (where MMP is matrix metalloproteinase) before and after antibiotic treatment in hospitalized adult patients with community-acquired pneumonia (CAP). Method: Plasma LCN2 and LCN2/MMP-9 complex levels were measured in 61 adult patients with CAP and 60 healthy controls using commercial enzyme-linked immunosorbent assay (ELISA). Results: A decrease in the number of white blood cells (WBCs) and neutrophils and decreases in the levels of C-reactive protein (CRP), LCN2, and LCN2/MMP-9 complex were observed after antibiotic treatment. The plasma level of LCN2, but not that of CRP, was correlated with the severity of CAP based on the Pneumonia Severity Index (PSI; r = 0.333, P = 0.009), confusion, urea, respiratory rate and blood pressure (CURB)-65 (r = 0.288, P = 0.024), and Acute Physiology And Chronic Health Evaluation II (APACHE II) scores (r = 0.328, P = 0.010). LCN2 levels were also significantly correlated with LCN2/MMP-9 levels and the numbers of WBCs or neutrophils. Conclusions: Plasma levels of LCN2 and the LCN2/MMP-9 complex can act as adjuvant diagnostic biomarkers for CAP. Plasma LCN2 might play a further role in the clinical assessment of the severity of CAP, which could potentially guide the development of future treatment strategies.",
keywords = "Community-acquired pneumonia, Lipocalin 2, Matrix metalloprotease-9, Pneumonia Severity Index",
author = "Yeh, {Yuan Hung} and Chang, {Junn Liang} and Hsiao, {Pei Ching} and Tsao, {Shih Ming} and Lin, {Chien Huang} and Kao, {Shang Jyh} and Chou, {Ming Chih} and Yang, {Shun Fa} and Chien, {Ming Hsien}",
year = "2013",
month = "7",
doi = "10.1002/jcla.21588",
language = "English",
volume = "27",
pages = "253--260",
journal = "Journal of Clinical Laboratory Analysis",
issn = "0887-8013",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia

AU - Yeh, Yuan Hung

AU - Chang, Junn Liang

AU - Hsiao, Pei Ching

AU - Tsao, Shih Ming

AU - Lin, Chien Huang

AU - Kao, Shang Jyh

AU - Chou, Ming Chih

AU - Yang, Shun Fa

AU - Chien, Ming Hsien

PY - 2013/7

Y1 - 2013/7

N2 - Background: The aim of this study was to investigate the differential plasma levels of lipocalin 2 (LCN2) and its complex with MMP-9 (where MMP is matrix metalloproteinase) before and after antibiotic treatment in hospitalized adult patients with community-acquired pneumonia (CAP). Method: Plasma LCN2 and LCN2/MMP-9 complex levels were measured in 61 adult patients with CAP and 60 healthy controls using commercial enzyme-linked immunosorbent assay (ELISA). Results: A decrease in the number of white blood cells (WBCs) and neutrophils and decreases in the levels of C-reactive protein (CRP), LCN2, and LCN2/MMP-9 complex were observed after antibiotic treatment. The plasma level of LCN2, but not that of CRP, was correlated with the severity of CAP based on the Pneumonia Severity Index (PSI; r = 0.333, P = 0.009), confusion, urea, respiratory rate and blood pressure (CURB)-65 (r = 0.288, P = 0.024), and Acute Physiology And Chronic Health Evaluation II (APACHE II) scores (r = 0.328, P = 0.010). LCN2 levels were also significantly correlated with LCN2/MMP-9 levels and the numbers of WBCs or neutrophils. Conclusions: Plasma levels of LCN2 and the LCN2/MMP-9 complex can act as adjuvant diagnostic biomarkers for CAP. Plasma LCN2 might play a further role in the clinical assessment of the severity of CAP, which could potentially guide the development of future treatment strategies.

AB - Background: The aim of this study was to investigate the differential plasma levels of lipocalin 2 (LCN2) and its complex with MMP-9 (where MMP is matrix metalloproteinase) before and after antibiotic treatment in hospitalized adult patients with community-acquired pneumonia (CAP). Method: Plasma LCN2 and LCN2/MMP-9 complex levels were measured in 61 adult patients with CAP and 60 healthy controls using commercial enzyme-linked immunosorbent assay (ELISA). Results: A decrease in the number of white blood cells (WBCs) and neutrophils and decreases in the levels of C-reactive protein (CRP), LCN2, and LCN2/MMP-9 complex were observed after antibiotic treatment. The plasma level of LCN2, but not that of CRP, was correlated with the severity of CAP based on the Pneumonia Severity Index (PSI; r = 0.333, P = 0.009), confusion, urea, respiratory rate and blood pressure (CURB)-65 (r = 0.288, P = 0.024), and Acute Physiology And Chronic Health Evaluation II (APACHE II) scores (r = 0.328, P = 0.010). LCN2 levels were also significantly correlated with LCN2/MMP-9 levels and the numbers of WBCs or neutrophils. Conclusions: Plasma levels of LCN2 and the LCN2/MMP-9 complex can act as adjuvant diagnostic biomarkers for CAP. Plasma LCN2 might play a further role in the clinical assessment of the severity of CAP, which could potentially guide the development of future treatment strategies.

KW - Community-acquired pneumonia

KW - Lipocalin 2

KW - Matrix metalloprotease-9

KW - Pneumonia Severity Index

UR - http://www.scopus.com/inward/record.url?scp=84880383786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880383786&partnerID=8YFLogxK

U2 - 10.1002/jcla.21588

DO - 10.1002/jcla.21588

M3 - Article

C2 - 23852780

AN - SCOPUS:84880383786

VL - 27

SP - 253

EP - 260

JO - Journal of Clinical Laboratory Analysis

JF - Journal of Clinical Laboratory Analysis

SN - 0887-8013

IS - 4

ER -